摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-氟喹啉-8-硼酸 | 1072951-45-1

中文名称
5-氟喹啉-8-硼酸
中文别名
——
英文名称
(5-fluoroquinolin-8-yl)boronic acid
英文别名
——
5-氟喹啉-8-硼酸化学式
CAS
1072951-45-1
化学式
C9H7BFNO2
mdl
MFCD11504850
分子量
190.969
InChiKey
HWFXMAQYNZHRLY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    391.4±52.0 °C(Predicted)
  • 密度:
    1.37±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.87
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    53.4
  • 氢给体数:
    2
  • 氢受体数:
    4

安全信息

  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:7bcd18144c07233277be2e5563b74af0
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 5-Fluoroquinoline-8-boronic acid
Synonyms: 5-Fluoroquinolin-8-ylboronic acid

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 5-Fluoroquinoline-8-boronic acid
CAS number: 1072951-45-1

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H7BFNO2
Molecular weight: 191.0

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS<br/>[FR] DÉRIVÉS DE QUINOLÉINE UTILISÉS EN TANT QU'INHIBITEURS DE L'INTÉGRINE ALPHA4BÊTA7
    申请人:GILEAD SCIENCES INC
    公开号:WO2020092375A1
    公开(公告)日:2020-05-07
    The present disclosure provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.
    本公开提供了如下所述的化合物的化学式(I)或其药用可接受的盐。本公开还提供了包含化合物的药物组合物的制备方法,制备化合物的方法以及治疗炎症性疾病的治疗方法。
  • [EN] FUSED TRICYCLIC KRAS INHIBITORS<br/>[FR] INHIBITEURS DE KRAS TRICYCLIQUES FUSIONNÉS
    申请人:INCYTE CORP
    公开号:WO2021211864A1
    公开(公告)日:2021-10-21
    Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    本文披露了式(I)的化合物,使用这些化合物抑制KRAS活性的方法以及包含这些化合物的药物组合物。这些化合物可用于治疗、预防或改善与KRAS活性相关的疾病或障碍,如癌症。
  • [EN] TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS<br/>[FR] COMPOSÉS TRICYCLIQUES EN TANT QU'INHIBITEURS DE KRAS
    申请人:INCYTE CORP
    公开号:WO2021142252A1
    公开(公告)日:2021-07-15
    Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer. (I)
    本文披露了一种I式化合物,以及使用这些化合物抑制KRAS活性的方法和包含这些化合物的药物组合物。这些化合物可用于治疗、预防或改善与KRAS活性相关的疾病或障碍,如癌症。
  • NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS
    申请人:Babaoglu Kerim
    公开号:US20130203727A1
    公开(公告)日:2013-08-08
    The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds of formula (I).
    本发明提供了公式(I)的化合物或其盐,如本文所述。本发明还提供了包含公式I化合物的药物组合物,制备公式(I)化合物的过程,用于制备公式I化合物的中间体以及使用公式(I)化合物治疗哺乳动物的HIV病毒增殖,治疗艾滋病或延缓艾滋病或ARC症状发作的治疗方法。
  • Naphth-2-ylacetic acid derivatives to treat AIDS
    申请人:Babaoglu Kerim
    公开号:US09102614B2
    公开(公告)日:2015-08-11
    The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds of formula (I).
    本发明提供公式(I)的化合物或其盐,如本文所述。本发明还提供包含公式I化合物的制药组合物,制备公式(I)化合物的方法,用于制备公式I化合物的中间体以及使用公式(I)化合物治疗HIV病毒的增殖,治疗艾滋病或延缓哺乳动物艾滋病或ARC症状的发作的治疗方法。
查看更多